Verona Pharma Announces November 2023 Investor Conference Participation

Rhea-AI Summary

Verona Pharma plc (VRNA) announces senior management will present a company overview at upcoming healthcare conferences in November 2023. The conferences include Jefferies London Healthcare Conference, Piper Sandler 35th Annual Healthcare Conference, and 6th Annual Evercore ISI HealthCONx Conference. Webcasts of each presentation will be available on the Company’s website. Contact information for investor and media inquiries is provided.

LONDON and RALEIGH, N.C., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will present a company overview at the following conferences in November 2023:

Jefferies London Healthcare Conference
Date: Wednesday, November 15, 2023
Time: 10:00 AM EST / 3:00 PM GMT
Location: London, UK

Piper Sandler 35^th Annual Healthcare Conference
Date: Tuesday, November 28, 2023
Time: 8:00 AM EST / 1:00 PM GMT
Location: New York, NY

6^th Annual Evercore ISI HealthCONx Conference
Date: Wednesday, November 29, 2023
Time: 2:35 PM EST / 7:35 PM GMT
Location: Miami, FL

A webcast of each conference presentation will be available on the Events and Presentations link on the Investors page of the Company’s website, www.veronapharma.com.

For further information please contact:

Verona Pharma plc	US Tel: +1-833-417-0262 UK Tel: +44 (0)203 283 4200
Victoria Stewart, Senior Director of Investor Relations and Communications	IR@veronapharma.com
Argot Partners US Investor Enquiries	Tel: +1-212-600-1902 verona@argotpartners.com
Ten Bridge Communications International / US Media Enquiries	Tel: +1-312-523-5016 tbcverona@tenbridgecommunications.com
Leslie Humbel

About Verona Pharma

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharma’s product candidate, ensifentrine, has the potential to become the first non-steroidal therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one molecule. The Company has evaluated nebulized ensifentrine in its Phase 3 clinical program ENHANCE (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) for COPD maintenance treatment. Ensifentrine met the primary endpoint in both ENHANCE-1 and ENHANCE-2 trials demonstrating statistically significant and clinically meaningful improvements in lung function. In addition, ensifentrine substantially reduced the rate and risk of COPD exacerbations in pooled analysis from ENHANCE-1 and ENHANCE-2. In the third quarter of 2023, the US Food and Drug Administration accepted for review the Company’s NDA for ensifentrine for the maintenance treatment of patients with COPD and assigned a PDUFA target action date of June 26, 2024. Two additional formulations of ensifentrine have been evaluated in Phase 2 trials for the treatment of COPD: dry powder inhaler (“DPI”) and pressurized metered-dose inhaler (“pMDI”). Ensifentrine has potential applications in cystic fibrosis, non-cystic fibrosis bronchiectasis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com

FAQ

What conferences will Verona Pharma present at in November 2023?

Verona Pharma will present at Jefferies London Healthcare Conference, Piper Sandler 35th Annual Healthcare Conference, and 6th Annual Evercore ISI HealthCONx Conference.

Where can I watch the webcast of the conference presentations?

The webcast will be available on the Events and Presentations link on Verona Pharma’s website.

How can I contact Verona Pharma for further information?

For further information, you can contact Verona Pharma via the provided US and UK telephone numbers or email addresses for investor and media inquiries.